Suchergebnisse - (Standardsuche:issn:"1756-8919" OR issn:"1756-8927")

PubPharm (13)

1

Targeting JNK and its role in tumor development and chemoresistance

enthalten in: Future medicinal chemistry | 2020

von Wu, Q. | Kuca, K. | Wu, W.

2

An update on chemical classes targeting ERK1/2 for the management of cancer

enthalten in: Future medicinal chemistry | 2020

von Pathania, S. | Rawal, R.

3

Reversible versus irreversible inhibition modes of ERK2 : a comparative analysis for ERK2 protein kinase in cancer therapy

enthalten in: Future medicinal chemistry | 2018

von Khan, S. | Bjij, I. | Betz, R. | +1

4

In vitro metabolism study of a novel P38 kinase inhibitor : in silico predictions, structure elucidation using MS/MS-I

enthalten in: Future medicinal chemistry | 2018

von Hashem, H. | Mahrouse, M.

5

JNK pathway signaling : a novel and smarter therapeutic targets for various biological diseases

enthalten in: Future medicinal chemistry | 2015

von Kumar, A. | Singh, U. | Kini, S. | +7

6

The RAF-MEK-ERK pathway : targeting ERK to overcome obstacles to effective cancer therapy

enthalten in: Future medicinal chemistry | 2015

von Yu, Z. | Ye, S. | Hu, G. | +4

7

TAK1 selective inhibition : state of the art and future opportunities

enthalten in: Future medicinal chemistry | 2015

von Kilty, I. | Jones, L.

8

Dual leucine zipper kinase as a therapeutic target for neurodegenerative conditions

enthalten in: Future medicinal chemistry | 2013

von Ferraris, D. | Yang, Z. | Welsbie, D.

9

JNK inhibitors as anti-inflammatory and neuroprotective agents

enthalten in: Future medicinal chemistry | 2013

von Graczyk, P.

10

What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?

enthalten in: Future medicinal chemistry | 2011

von Millan, D.